Case report

*Edwardsiella tarda* bacteremia with metastatic gastric cancer

Kazuhiro Nishida*, Takaharu Kato, Ikki Yuzaki, Toshiyuki Suganuma

**Department of Surgery, Yokosuka General Hospital Uwamachi, 2-36 Uwamachi Yokosuka City, Kanagawa, 238-8567, Japan**

**ABSTRACT**

*Edwardsiella tarda* (E. tarda) is a rare human pathogen; however, the overall mortality of bacteremia is reported to be up to 50%. Here, we describe a case of cholangitis with *E. tarda* bacteremia who had a pancreatoduodenectomy for a locally advanced gastric cancer. He was successfully treated using a cefmetazole, a second generation cephalosporin for 14 days. To the best of our knowledge, this is the first case report about *E. tarda* bacteremia after biliary reconstruction.

**Introduction**

*Edwardsiella tarda* (E. tarda) is an unusual human pathogen that can cause gastroenteritis, soft tissue infection, myonecrosis, bacteremia, cholecystitis, liver abscess, osteomyelitis, and tuboovarian abscess [1–4]. The most frequent manifestation is gastroenteritis and the least frequent is extra-intestinal infection. Immunocompromised patients are more vulnerable to infection and their mortality rate is reported to be about 50% when associated with bacteremia [1,5]. This article describes a case of a metastatic gastric cancer patient infected with *E. tarda* bacteremia who was successfully treated with antimicrobials.

**Case presentation**

A 78 year old man came to our hospital complaining of a high grade fever and a shaking chill. He has undergone a pancreatoduodenectomy for a locally advanced gastric cancer two years before, and a liver metastasis was found three months after surgery. His body temperature was 39.1°C and his abdomen was not painful. The patient was diagnosed with retrograde cholangitis on the basis of his recurrent episodes of cholangitis after surgery and having liver function enzymes elevated beyond normal range. We begun antimicrobial therapy with cefmetazole. *E. tarda* was identified from the blood culture as a causative agent and it was discovered that he had eaten raw seafood two days before his admission day (Chart 1). After 14 days of antimicrobial therapy he was discharged without any complications.

**Discussion**

*E. tarda* is a nonfermenting gram-negative bacilli which is identified apart from Salmonella species for producing hydrogen sulfide and indole; and also fermenting only glucose and maltose. It is a member of *Enterobacteriaceae*, but rarely colonizes in the human gastrointestinal tract, reported to be found only in 26 of 353,600 Japanese individuals [6]. They are commonly isolated from fresh water environments and habituating animals such as fish and reptiles. Contact with these animals and consumption of contaminated food, e.g., sushi, raw fish, and raw meat, are considered as risk factors of *E. tarda* infection [4,5,7,8]. Hirai et al. showed that 45.5% of cases of bacteremia have been reported in Japan, where many brackish water areas and rivers are found and much raw seafood is eaten. They also studied the seasonal distribution of all patients infected with *E. tarda*; 77.2% of bacteremia occurred between July and November [5]. Other well established risk factors of the host are hepatobiliary diseases, malignancy, and diabetes mellitus [9].

Our patient had a clinical history of developing a liver metastasis of the gastric cancer, and an episode of having eaten sushi in July. In addition, he had undergone a pancreatoduodenectomy and biliary reconstruction which may have allowed the bacteria to more easily enter bloodstream from the intestines.
Once bacteremia has occurred, the mortality ranges from 40 to 50%, [1,5,9] regardless of its sensitivity to antimicrobials. In the literature, penicillins, cephalosporins and carbapenems are often utilized. Our patient had a recurrent episode of retrograde cholangitis caused by Escherichia coli with extended spectrum beta lactamase. Based on the evidence that cefmetazole is effective against extended spectrum beta lactamase producing Enterobacteriaceae [10], we began the antimicrobial treatment with cefmetazole and were successful.

**Conclusion**

A liver metastatic gastric cancer patient with *E. tarda* bacteremia was treated successfully with cefmetazole, a second generation cephalosporin. To the best of our knowledge, this is the first case report about *E. tarda* bacteremia after pancreatoduodenectomy.

**Funding sources**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] Janda JM, Abbott SL. Infections associated with the genus Edwardsiella: the role of Edwardsiella tarda in human disease. Clin Infect Dis 1993;17:742–8.
[2] Golub V, Kim AC, Kro I. Surgical wound infection, tuboovarian abscess, and sepsis caused by Edwardsiella tarda: case reports and literature review. Infection 2010;38:487–9.
[3] Ohara Y, Kikuchi O, Goto T, Yoshiha T, Mori H, Matsueda K, et al. Successful treatment of a patient with sepsis and liver abscess caused by Edwardsiella tarda. Intern Med 2012;51:2813–7.
[4] Slaven EM, Lopez FA, Hart SM, Sanders CV. Myonecrosis caused by Edwardsiella tarda: a case report and case series of extraintestinal E. tarda infections. Clin Infect Dis 2001;32:1430–3.
[5] Hirai Y, Asahata-Tago S, Ainoa Y, Fujita T, Kikuchi K. Edwardsiella tarda bacteremia: a rare but fatal water- and foodborne infection: review of the literature and clinical cases from a single centre. Can J Infect Dis Med Microbiol 2015;26:313–8.
[6] Nagel P, Serritella A, Layden T. Edwardsiella tarda gastroenteritis associated with a pet turtle. Gastroenterology 1982;82:1436–7.
[7] Vandepitte J, Lemmens P, De Swert L. Human Edwardsielliosis traced to ornamental fish. J Clin Microbiol 1983;17:165–7.
[8] Wang IK, Kuo HL, Chen YM, Lin CL, Chang HY, Chuang FR, et al. Extrainestinal manifestations of Edwardsiella tarda infection. Int J Clin Pract 2005;59:917–21.
[9] Doi A, Shindma T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis 2013;17(3):e159-63, doi:http://dx.doi.org/10.1016/j.ijid.2012.09.010.